Hims & Hers (HIMS) stock falls over 25% as Novo Nordisk (NVO) files patent lawsuit targeting semaglutide products. FDA crackdown on unapproved GLP-1 compounding forces HIMS to drop new $49 oral Wegovy alternative. Stock down 45% YTD, with BofA cautioning against buying due to legal risks and potential injunctions on GLP-1 products.

Analysts warn of legal defense costs and potential injunctions affecting HIMS stock. Transition away from high-margin compounded drugs could lead to negative earnings in 2026. NVO testing finds impurities up to 86% in compounded samples, damaging HIMS brand. Stock trading below key moving averages, indicating sustained downward momentum.

BofA maintains “Underperform” rating on HIMS, lowers price target to $13. Analysts suggest pivot towards talent and supply chain investments. Other firms see selloff as overdone, with consensus “Hold” rating and $39 target implying 100% upside potential. Stock may face mass subscriber exodus and brand damage from impurities found in compounded samples.

Read more at Yahoo Finance: As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?